Former Chief Scientific Officer · Dianthus Therapeutics, Inc. (DNTH)

Lisa Olson

FY2023 is the first fiscal year CompBrief holds for Lisa Olson as a named executive officer of Dianthus Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,128,013

Salary $160,730Stock awards $0Bonus $277,027

3rd of 7 named executive officers at Dianthus Therapeutics by FY2023 total.

7 named officers on file for Dianthus Therapeutics, FY2023

Lisa Olson’s pay file — $29

  • 1 fiscal year of pay, line by line
  • DNTH’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Dianthus Therapeutics’s whole pay program stands against its peers

  • Dianthus Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DNTH→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 11, 2024 (DEF 14A).

Free

Get Lisa Olson’s full pay file as a PDF — free

More than this page: up to 10 years of Lisa’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Lisa Olson compensation by year

Dianthus Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Dianthus Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$160,730
Bonus$277,027
Stock awards$0
Option awards$91,863
Non-equity incentive$0
Pension and deferred compensation$0
All other$598,393
Total$1,128,013

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Dianthus Therapeutics, Inc. DEF 14A filed April 11, 2024, accession 0000950170-24-043693, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Dianthus Therapeutics, Inc. filed document, accession 0000950170-24-043693. Every figure is read from that document and cited to the page and table it appears in. Filed April 11, 2024.

Dianthus Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Stephen MahoneyFormer President, Chief Financial and Operating Officer$1,656,676
Thomas BeethamFormer Chief Legal Officer$1,571,434
Lisa Olson · this pageFormer Chief Scientific Officer$1,128,013
Jason GardnerFormer President and Chief Executive Officer$667,649
Marino GarciaPresident and Chief Executive Officer$496,022
Simrat RandhawaChief Medical Officer$338,158
Ryan SavitzChief Financial Officer, Chief Business Officer and Treasurer$329,651

The full Dianthus Therapeutics compensation record

free company brief

This page is one person within Dianthus Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Dianthus Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Dianthus Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Lisa Olson's compensation dossier · One-time report. No refunds.